Literature DB >> 11226061

Regulation and manipulation of angiogenesis in the primate corpus luteum.

H M Fraser1, S F Lunn.   

Abstract

Intense physiological angiogenesis occurs during the early stages of luteal development, providing a model in which the complex processes regulating the angiogenic pathway may be studied. Here, a working hypothesis is presented to explain the diverse changes in the vasculature of the corpus luteum that occur over a short period, based around changes in vascular endothelial growth factor, the angiopoietins and matrix metalloproteinases. An illustration is given of how angiogenesis can be monitored in a primate model and how the role of individual angiogenic factors such as vascular endothelial growth factor may be explored in vivo. Because of the marked effect of inhibition of angiogenesis on luteal function, it is predicted that the normal processes of follicular development, ovulation and luteal function could all be profoundly influenced by the manipulation of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226061     DOI: 10.1530/rep.0.1210355

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  13 in total

Review 1.  Angiogenesis in the female reproductive organs: pathological implications.

Authors:  Lawrence P Reynolds; Anna T Grazul-Bilska; Dale A Redmer
Journal:  Int J Exp Pathol       Date:  2002-08       Impact factor: 1.925

2.  Mathematical analysis of a model for the growth of the bovine corpus luteum.

Authors:  Sotiris A Prokopiou; Helen M Byrne; Mike R Jeffrey; Robert S Robinson; George E Mann; Markus R Owen
Journal:  J Math Biol       Date:  2013-12-13       Impact factor: 2.259

Review 3.  Angiogenesis in the human corpus luteum.

Authors:  Norihiro Sugino; Aki Matsuoka; Ken Taniguchi; Hiroshi Tamura
Journal:  Reprod Med Biol       Date:  2008-04-17

4.  Generation of mice expressing only the long form of the prolactin receptor reveals that both isoforms of the receptor are required for normal ovarian function.

Authors:  Jamie A Le; Heather M Wilson; Aurora Shehu; Jifang Mao; Y Sangeeta Devi; Julia Halperin; Tetley Aguilar; Anita Seibold; Evelyn Maizels; Geula Gibori
Journal:  Biol Reprod       Date:  2012-03-22       Impact factor: 4.285

5.  Nanoparticles Accumulate in the Female Reproductive System during Ovulation Affecting Cancer Treatment and Fertility.

Authors:  Maria Poley; Patricia Mora-Raimundo; Yael Shammai; Maya Kaduri; Lilach Koren; Omer Adir; Jeny Shklover; Janna Shainsky-Roitman; Srinivas Ramishetti; Francis Man; Rafael T M de Rosales; Assaf Zinger; Dan Peer; Irit Ben-Aharon; Avi Schroeder
Journal:  ACS Nano       Date:  2022-03-16       Impact factor: 18.027

6.  Comparison of endocrine and cellular mechanisms regulating the corpus luteum of primates and ruminants.

Authors:  M C Wiltbank; S M Salih; M O Atli; W Luo; C L Bormann; J S Ottobre; C M Vezina; V Mehta; F J Diaz; S J Tsai; R Sartori
Journal:  Anim Reprod       Date:  2012-07       Impact factor: 1.807

7.  Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation.

Authors:  Annunziata Mauro; Alessandra Martelli; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Oriana Di Giacinto; Mauro Mattioli; Barbara Barboni
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

8.  Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides.

Authors:  Patrick Ying Kit Yue; Nai Ki Mak; Yuen Kit Cheng; Kar Wah Leung; Tzi Bun Ng; David Tai Ping Fan; Hin Wing Yeung; Ricky Ngok Shun Wong
Journal:  Chin Med       Date:  2007-05-15       Impact factor: 5.455

Review 9.  Microvascular endothelial cells of the corpus luteum.

Authors:  John S Davis; Bo R Rueda; Katherina Spanel-Borowski
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

Review 10.  Angiogenesis in the corpus luteum.

Authors:  Hamish M Fraser; Christine Wulff
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.